BVT-2733
BVT-2733 is an inhibitor of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) that exhibits anti-diabetic, anti-inflammatory, and anti-osteoporotic properties. BVT-2733 decreases blood glucose and serum insulin levels in animal models of hyperglycemia. BVT-2733 also attenuates arthritis severity, decreases pro-inflammatory cytokine production, and suppresses synovial inflammation. In other animal models, this compound prevents 11βHSD-induced osteogenic differentiation and suppression of osteogenesis.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18845608
| Cas No. |
376640-41-4 |
|---|---|
| Formula |
C17H21ClN4O3S2 |
| Formula Wt. |
428.96 |
| IUPAC Name |
3-Chloro-2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide |
| Synonym |
BVT2733 |
Zhang L, Dong Y, Zou F, et al. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. Int Immunopharmacol. 2013 Nov;17(3):489-94. PMID: 23938253.
Wu L, Qi H, Zhong Y, et al. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction. Endocr J. 2013;60(9):1047-58. PMID: 23759754.
Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002 Nov;45(11):1528-32. PMID: 12436336.
